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Letters to the Editortotal. In the United Kingdom, approxi-
mately 3500 isolated bioprosthetic aor-
tic valve replacements are performed
per annum.Assuming 50% of these pa-
tients are eligible for the study and all
units participate, the study will take
more than 4 years to complete.
One of the main difficulties we
have encountered in the feasibility
phase of this study is recruitment of
patients with pure aortic valve
disease who do not have any forms
of arrhythmia or coronary artery
disease, thus already receiving aspirin
or warfarin. Ideally, a randomized
study is necessary. Unless this is
a multicenter international trial, suffi-
cient numbers of patients cannot be
recruited. We may then have to rely
on antithrombotic therapy in the
high-risk groups.
We would like to thank the British Heart
Foundation for supporting the feasibility
phase of this study.
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We thank the authors for their
comments regarding our recent article
discussing the necessity of immediate
postoperative anticoagulation in pa-
tients with bioprosthetic aortic valves.1
Although this exact topic has been
studied repeatedly over the past de-
cade, there continues to be a lack of
consensus, primarily owing to the ab-
sence of level 1 evidence. As the au-
thors point out, despite strong
evidence to advocate for/against an-
tithrombotic therapy after biopros-
thetic aortic valve replacement,
guidelines from major international
cardiology and cardiac surgery socie-
ties continue to recommend antithrom-
botic therapy for 90 days after
bioprosthetic aortic valve replacement.
Although there have been attempts
at performing a prospective randomized
controlled trial to definitively answer
this question and establish a standard
of care,2,3 these studies have been
grossly underpowered, containing no
more than 150 patients in each group.
Depending on the parameters used to
performapower analysis, a conservative
estimate for conducting a randomized
controlled trial with an effective power
(b> 80%) would consist of at least
1500 patients in each group. As the au-
thors describe, conducting such a study
would require enrollment from multiple
high-volume centers.
The controversy and need for level 1
evidence regarding this topic are illus-
trated by the variability in antithrom-
botic therapy regimens, which has
been documented in the literature (pri-
marily in the United Kingdom).4 An-
ecdotally, in the United States, we
know of institutions and surgeons
that routinely anticoagulate with intra-
venous heparin followed by warfarin
sodium and those that provide no anti-
coagulation whatsoever. These vary-
ing practices and unclear data should
provide incentive to funding agencies
to further study this question. On one
hand, we may be placing patients at
a high risk of major bleeding events
and on the other hand, we may notCardiovascular Surgery c November 20be adequately protecting patients
from the risk of embolism. In the
meantime, however, we believe it is
important that we use the best
available evidence, which is to avoid
routine anticoagulation except in
high-risk patients.1
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ENDOVASCULAR TREATMENT
FOR TYPE B AORTIC
DISSECTIONSTo the Editor:
We read with great interest the man-
uscript by Xu and associates,1 in
which they presented their early and
midterm results of endovascular repair
for the treatment of type B aortic dis-
sections.
Although the Stanford classification
is frequently used in the current era,
the DeBakey classification seems more10
Letters to the Editorapplicable when considering thoracic
endovascular aortic repair (TEVAR)
for dissections.2 DeBakey type III dis-
sections are divided into 2 groups:
type IIIa, in which the dissection is con-
fined to the supradiaphragmatic de-
scending aorta, and type IIIb, in which
it extends beyond the diaphragm. Defi-
nition is important from the point of
achieving false lumen–free treatment
or only aneurysm exclusion with TE-
VAR. According to our modest experi-
ence, we3 obtained ‘‘cure’’ with
TEVAR in patients with type IIIa dis-
sections by coverage of the proximal
tear and complete reattachment of the
intima and media levels.2
Endovascular treatment is per-
formed to exclude the aneurysm in
type IIIb dissections.2,4 However, pa-
tency of the false lumen is a major
prognostic factor in the mid to long
run in patients with type IIIb aortic dis-
sections both after open repair5 and af-
ter TEVAR.2,4 After TEVAR, the
proximal false lumen does not always
thrombose and blood flow may con-
tinue outside the stent graft.2 This
may increase the size of the aneurysm,
lead to a new aneurysm formation at
the excluded segment of the aorta, or
even lead to collapse of the stent graft
system.2 The postoperative course
marked by such a complication in 1
of our patients (Figure E1), who was
further treated with TEVAR.
Even if the proximal false lumen
completely thromboses, it is still under
the stress of systemic blood pressure.
In contrast to the theory that thick
thrombus protects from rupture, intra-
aortic thrombus diminishes aortic
wall nourishment, and ruptures fre-
quently occur in the presence of aortic
thrombus.
In brief, TEVAR fails to completely
compress the false lumen in chronic
type IIIb dissections either because of
high pressure inside the false lumen
or because it is intended not to, since
some visceral arteries may originate
from this lumen. The issue is different
during surgery or perioperative hybrid
therapy. Surgical treatment mediatesThe Journalreplacement of the dilated segment of
aorta. Distal anastomosis may provide
perfusion of only the true lumen or
both lumina.5 And TEVAR during
surgical treatment differs from con-
ventional deployment, in which stent
grafts are delivered and expanded
into a pressureless aorta, a technique
that has better success rates on fol-
low-up.4
Once again, we congratulate the au-
thors for their very valuable contribu-
tion. We believe surgical treatment
still seems the valid option for the
treatment of chronic type B dissections
with low complication rates in experi-
enced centers in the current era.5
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ISCHEMICCARDIOMYOPATHY:
IS THE CLEVELAND CLINIC
MODELVALID?
To the Editor:
Clinically significant variables are
required before any statistical model
can provide useful decision making
during surgical management of ische-
mic cardiomyopathy. Models would
otherwise be created with an insuffi-
cient database, so that statistically val-
idated results might yield valueless
clinical conclusions that might worsen
the development of congestive heart
failure (CHF) symptoms and fatal ven-
tricular arrhythmias after their applica-
tion to the enormous population with
CHF.
The recent Cleveland Clinic
Foundation (CCF) report1 concludes
that coronary artery bypass grafting
(CABG) alone or in combination
with surgical ventricular restoration
(SVR) provides similar long-term re-
sults to the recent National Institutes
of Health Surgical Treatment of Ische-
mic Heart Failure (STICH) trial that
evaluated quality-of-life outcome,
rehospitalization rate, andmortality af-
ter surgical management of ischemic
cardiomyopathy.2 Their findings es-
tablish CABG therapy alone as a suffi-
cient treatment, fulfill current
angioplasty revascularization goals,
diminish cardiologic interest in SVR,
and limit expansion of the surgeon’s
interest in learning a new procedure
for CHF management.
The innovative statistical model hy-
pothesis of no outcome difference be-
tween CABG versus CABG with
SVR becomes invalid if the ischemic
cardiomyopathy clinical database
does not show increased left ventricu-
lar end-systolic volume index
(LVESVI) rather than reduced systolic
ejection fraction3 as the indicator of
heart failure. The original STICH trial
entry criteria required a preoperative
LVESVI of greater than 60 mL/m2,
as measured by means of cardiac mag-
netic resonance imaging or single pho-
ton emission computed tomographyy c Volume 140, Number 5 1203
FIGURE E1. Complicated stent graft treatment of chronic type IIIb aortic dissection.
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